|1.||Ryan, Anderson J: 23 articles (01/2014 - 12/2002)|
|2.||Heymach, John V: 13 articles (07/2015 - 07/2006)|
|3.||Ciardiello, Fortunato: 13 articles (05/2014 - 12/2002)|
|4.||Herbst, Roy S: 10 articles (01/2015 - 02/2007)|
|5.||Tortora, Giampaolo: 10 articles (02/2011 - 12/2002)|
|6.||Ryan, Anderson: 10 articles (11/2009 - 01/2004)|
|7.||Schlumberger, Martin: 8 articles (04/2015 - 02/2010)|
|8.||Langmuir, Peter: 8 articles (04/2012 - 09/2007)|
|9.||Johnson, Bruce E: 7 articles (06/2011 - 09/2007)|
|10.||Troiani, Teresa: 7 articles (11/2007 - 04/2003)|
10/01/2014 - "Compared with the overall study population, in which progression-free survival (PFS) [hazard ratio (HR) = 0.79] but not OS (HR = 0.91) were significantly improved with vandetanib, there was greater relative clinical benefit for patients with EGFR mutation-positive tumors [PFS HR 0.51, confidence interval (CI) 0.25-1.06 and OS HR 0.46, CI 0.14-1.57] and EGFR FISH-positive tumors (PFS HR 0.61, CI 0.39-0.94 and OS HR 0.48, CI 0.28-0.84). "
11/01/2009 - "The tumor growth delay kinetics observed in this study of the LoVo colorectal model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy may be beneficial in tumors of this type."
12/01/2004 - "These studies demonstrate that the additional EGFR TKI activity may contribute significantly to the antitumor efficacy of ZD6474, in particular in those tumors that are dependent on continued EGFR-signaling for proliferation or survival. "
08/01/2015 - "After one month of 300 mg/day vandetanib treatment, a biochemical and clinical response of the ECS was achieved but it did not result in significant reduction of tumor burden. "
08/15/2002 - "Histological analysis of Calu-6 tumors treated with 50 mg/kg/day ZD6474 for 24 days showed a significant reduction (>70%) in CD31 (endothelial cell) staining in nonnecrotic regions. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2007 - "Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer."
12/01/2013 - "This randomized, phase II study investigated whether benefit could be obtained by giving vandetanib, an oral inhibitor of vascular endothelial and epithelial growth factor receptor, as a maintenance treatment in non-small cell lung cancer (NSCLC). "
03/01/2012 - "The aim of this study is to evaluate the efficacy and safety of vandetanib as a second-line treatment for advanced non-small cell lung cancer (NSCLC). "
12/01/2011 - "The purpose of this study was to assess the efficacy and toxicity of vandetanib in the second-line treatment for advanced non-small cell lung cancer (NSCLC). "
12/01/2011 - "The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials."
|3.||Breast Neoplasms (Breast Cancer)
01/01/2013 - "Breast cancer cells were exposed to UV-B and ZD6474 and the cell viability, apoptosis, invasion and motility studies were conducted for the combinatorial effect. "
09/01/2014 - "Vandetanib has demonstrated a modest efficacy in patients with metastatic breast cancer. "
09/01/2014 - "Vandetanib as a potential treatment for breast cancer."
04/15/2010 - "ZD6474 coerces breast cancer for an apoptotic journey."
04/15/2010 - "We hypothesized that inhibition of phosphorylation of the EGFR and VEGFR by ZD6474 would inhibit breast cancer cell proliferation and induce apoptosis. "
|4.||Neoplasm Metastasis (Metastasis)
01/01/2015 - "One of 20 symptomatic patients with MTC bone metastases after surgery received vandetanib therapy for 20 months and responded well. "
04/21/2009 - "Vandetanib (25 mg kg(-1) day(-1)) also significantly (P=0.006) prolonged the time to metastasis in an intravenous model of TKKK metastasis. "
10/01/2015 - "Treatment with vandetanib, a RET inhibitor was initiated; his metastatic disease has been stable, without symptoms or recurrent cutaneous metastasis, for 2 years following the discovery of his metastatic nose tumor. "
09/01/2012 - "Two patients in the vandetanib group and one in the placebo group died from treatment-related serious adverse events (haemorrhage from skin metastases and pneumonia in the vandetanib group and pneumonia in the placebo group). "
09/01/2010 - "In vivo, ZD6474 significantly enhanced the anti-metastasis effects of radiation, while treatment with radiation and ZD6474 was found to be well tolerated and resulted in a strong inhibition of tumor growth. "
|5.||Thyroid Neoplasms (Thyroid Cancer)
04/01/2011 - "At least one randomized, placebo-controlled phase III trial has been successfully completed, showing improved progression-free survival in patients with advanced or metastatic medullary thyroid carcinoma treated with vandetanib. "
06/01/2013 - "Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study."
09/01/2012 - "Vandetanib is the first targeted drug to show evidence of efficacy in a randomised phase 2 trial in patients with locally advanced or metastatic differentiated thyroid carcinoma. "
09/01/2012 - "Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial."
07/01/2015 - "Vandetanib statistically prolonged PFS in comparison with the placebo (30.5 vs. 19.3 months, hazard ratio 0.46), It even prolonged PFS in surgically unresectable or metastatic differentiated thyroid cancer cases compared with the placebo (11.1 vs. 5.9 months, hazard ratio 0.63). "
|1.||N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Epidermal Growth Factor Receptor (EGF Receptor)
|5.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||erlotinib (CP 358,774)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)